Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Molecular Targets for Squamous NSCLC: Rounding Out Our ASCO 2012 Lung Cancer Highlights Presentations
Author
Howard (Jack) West, MD

The last topic covered by Dr. Neal was on exciting work on molecular targets for squamous NSCLC. Long the poor stepchild to adenocarcinoma and other non-squamous subtypes, where new targets have been identified and several exciting targets tested and some now available, squamous NSCLC has largely been defined over the past few years by all of the things not appropriate for it: Avastin (bevacizumab) due to excessive bleeding risk, Alimta (pemetrexed) due to lack of activity, molecular testing for an EGFR mutation or ALK rearrangement due to a low probability of a positive result. But new work from a couple of different groups, as summarized by Dr. Neal, suggests that there are indeed potentially treatable molecular targets in squamous NSCLC, and this could lead to many new trials and therapeutic options for this subset of patients in the coming years.

Here are the video and audio versions of the podcast, along with the transcript and figures for this short program.

Dr. Neal ASCO 2012 LC Highlights Molec Targets Squamous NSCLC Audio Transcript

Dr. Neal ASCO 2012 LC Highlights 2012 Molec Targets Squamous NSCLC Transcript

Dr. Neal ASCO 2012 LC Highlights Molec Targets Squamous NSCLC Figs

We'll end with the question and answer session from that live program, coming up soon.

Next Previous link

Previous PostNext Post

Related Content

Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!

Forum Discussions

Can SCLC also be treated with targeted therapy?

Hi amitchouhan,

Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...

I was searching for this, Thank you so much for the info.

Glad to help.  FYI, I just edited the link, which has the agenda and links to oncologists' bios. Plus, the link is also on our home page, https://cancergrace.org/

Hope to see...

Recent Comments

JOIN THE CONVERSATION
Glad to help.  FYI, I just…
By JanineT GRACE … on
I was searching for this,…
By LilahStapleton on
Hi and welcome.  I'm sorry…
By JanineT GRACE … on
Hi amitchouhan,

Welcome to…
By JanineT GRACE … on